



# Personalized Medicine Therapy in Type 2 Diabetes Mellitus

<sup>1</sup>Rounak Aijaz, <sup>2</sup>Fariya Waseem, <sup>3</sup>Atiqua Warisa, <sup>4</sup>Mohd Kalim, <sup>5</sup>Ashutosh Kumar Tiwari, <sup>6</sup>Zeeshan Ali

<sup>4</sup>Assistant Professor,

<sup>1</sup>Department of Pharmacy,

<sup>1</sup>Kanpur Institute of Technology and pharmacy, Kanpur, India

**Abstract:** Type 2 diabetes mellitus (T2DM) present significant health challenges due to its different response to treatment. Personalized therapy approaches for managing type 2 diabetes is studied in this systematic review. Precision medicine uses digital technologies, biomarkers, lifestyle factors, and genetic profiles to provide therapy to each person for better results. One of the most important areas is pharmacogenomics, which looks for gene variants that affect drugs like metformin and sulfonylureas to help people select the right drug and dose. Biomarkers such as C-peptide and HbA1c changes how doctors conclude on treatment. Customized medication classes meet the persons needs. For example, SGLT2 inhibitors are for people with heart or kidney problems ,and GLP-1 receptor agonists are for people who are obese.

Digital health devoplmnts like AI algorithms and constant glucose monitoring give you real-time data so you can make changes before they happen. Lifestyle management asses environmental factors and nutrigenomics to make them more efficient. Implementation is obstructed by the high costs of genetic testing, constrained access in developing countries, the lack of standardized protocols, and concerns related to data privacy, even after potential advantages such as good glycemic control and reduced difficulty. Future guidance include indicative modeling, longer treatments, and integrating different types of omics. This review emphasizes the need for continued research to aid equitable clinical adoption, while demonstrating precision medicine's capacity to change T2DM management from broad to customized strategies.

**Keywords:** Precision medicine , Type 2 Diabetes , Pharmacogenomics , Personalized therapy , Digital health

## I. Introduction

Type 2 diabetes mellitus (T2DM) is a frequent health problem worldwide. When the body can't produce enough insulin or utilise completly, this occurs. This causes blood sugar levels to increase. Over time, it can create cardiac issues, nephron dysfunction, nerve damage, and limited vision. A lot of people have type 2 diabetes, but not everyone responds to simple treatments like medications, insulin shots, diet alterations, and exercise. Some people respond well to a medication, but others have negative side effects or don't get any benefit at all.

Personalized therapy methods give people a new chance. This method doesn't use a "one size fits all" approach; instead, it looks at each patient's unique needs. Doctors look at a person's genes, their physical traits, their environment, and their way of life.

For example, genetic testing can show whether a drug like metformin will give results best or create problems. Blood markers like HbA1c or C-peptide help to track of growth and pick the right medicine. SGLT2 inhibitors help people with nephron problems, and new drugs like GLP-1 agonists are good for overweight patient who are prone to heart problems. Singh et al., 2026 This review compiles evidence from various studies. It looks at how personalized care can make life better, decrease the risk of complications, and help control blood sugar levels. AI, apps, and continuous glucose monitors are some examples of

handytools. They give real time information so you can make better choices. Although pricing are high and access is limited, future advancements in genomics and technology promise better results.

In short, individualized approaches to diabetes care get rid of guesswork and replace it with accuracy. They want care that is personalized, safer, and more effective. This study looks at the science, benefits, problems, and future directions for managing type 2 diabetes. Peter & Lupsa, 2019

## II. Concept of Precision Medicine in Diabetes

Precision medicine transforms the treatment of diabetes. It tailors care to the need of each individual. There will be no more "one size fits all." To determine the appropriate course of action, doctors consider environmental factors, habits, bodily indications, and genetics. Millions of people have type 2 diabetes. The heart, eyes, kidneys, and nerves are all harmed by high blood sugar. Some people respond well to standard medications like insulin or metformin, while others do not. Poor outcomes or side effects are common. This is corrected by precision medicine. It examines the reasons behind patient differences. Klonoff et al., 2020

Key parts make it work. First, genes matter. Tests check DNA for drug response. For example, some gene types predict if sulfonylureas will lower sugar fast. Second, biomarkers guide choices. HbA1c shows average sugar. C-peptide measures insulin output. These sort patients into groups.

Lifestyle counts too. Diets based on genes (nutrigenomics) help. Custom exercise plans build on age and fitness. Environment like stress or pollution affects risks. Tech adds power. Continuous glucose monitors (CGM) give real-time data. AI apps predict sugar drops and suggest fixes.

This approach beats trial-and-error. It picks drugs like GLP-1 agonists for overweight patients or SGLT2 inhibitors for heart issues. Studies show better sugar control, fewer problems, and happier lives.[ Merino & Florez, 2018]

Experts from ADA and EASD agree. Precision medicine uses layers of data: genes, proteins, and habits. It spots subtypes of diabetes for exact care. Challenges exist, like cost. But advances in cheap tests and AI promise wide use. In short, precision medicine turns data into action. It makes diabetes simple to manage. Patients get safer, smarter treatment. This leads to longer, healthier lives.

## III. Pharmacogenomics in Diabetes Management

Pharmacogenomics studies how genes affect drug responses in diabetes. It helps pick the right medicine and dose for each person. This cuts side effects and improves sugar control. Pearson, 2019

In diabetes management, drugs like metformin, sulfonylureas, or GLP-1 agonists work differently. Genes control drug uptake, breakdown, and action. For example, SLC22A1 gene variants change metformin transport into cells. Poor versions mean less effect. KCNJ11 or ABCC8 genes affect sulfonylureas. Some types boost insulin release well; others raise low sugar risk. Zeng et al., 2020

Tests scan these genes before starting drugs. Results guide choices. This is personalized medicine in action.

### Key Examples

- **Metformin:** OCT1 gene (SLC22A1) variants reduce response in 30-40% of patients. Tests spot non-responders early.
- **Sulfonylureas:** KCNJ11 changes predict good results or side effects like hypoglycemia.
- **GLP-1 agonists:** Gene markers like TCF7L2 link to better weight loss and sugar drop.
- **TZDs (pioglitazone):** PPARG variants improve heart benefits but raise fluid risks.

Monogenic diabetes, like MODY, uses genes to switch from insulin to pills.

It skips trial-and-error. Patients get faster control, fewer visits, and lower costs. Studies show 20-50% better HbA1c drops. It fits diverse groups, key in places like India.

### Challenges and Future

Tests cost money and need more data from all races. AI and cheap sequencing help. Soon, routine use in clinics.

Pharmacogenomics turns genes into better diabetes care. It promises safer, smarter treatment for Type 2 Diabetes.

#### IV. Role of Biomarkers in Personalized Therapy

Biomarkers play a crucial role in helping the treatment decisions:

- HbA1c for long-term glucose monitoring
- C-peptide levels for insulin secretion into cells. Poor versions mean less effect. KCNJ11 or ABCC8 genes affect sulfonylureas. Some types boost insulin release well; others raise low sugar risk. Pearson, 2019 Zeng et al., 2020 Tests scan these genes before starting drugs. Results guide choices. This is personalized medicine in action.

##### Key Examples

- **Metformin:** OCT1 gene (SLC22A1) variants reduce response in 30-40% of patients. Tests spot non-responders early. Venkatachalapathy et al., 2021
- **Sulfonylureas:** KCNJ11 changes predict good results or side effects like hypoglycemia.
- **GLP-1 agonists:** Gene markers like TCF7L2 link to better weight loss and sugar drop.
- **TZDs (pioglitazone):** PPARG variants improve heart benefits but raise fluid risks.
- Monogenic diabetes, like MODY, uses genes to switch from insulin to pills.

It skips trial-and-error. Patients get faster control, fewer visits, and lower costs. Studies show 20-50% better HbA1c drops. It fits diverse groups, key in places like India.

##### Challenges and Future

- Tests cost money and need more data from all races. AI and cheap sequencing help. Soon, routine use in
- Pharmacogenomics uses genes to improve diabetes treatment. It promises Type 2 Diabetes treatment that is safer and more intelligent.
- Genetic indicators of susceptibility to illness

These indicators help stratify patients and tailor therapeutic strategies accordingly.

#### V. Personalized Drug Therapy

The ideal medication is chosen for each diabetic patient through personalized medication therapy. Age, weight, genes, other diseases, and risks are all examined.

Williams et al., 2022

Doctors match drugs to patient needs. For example, GLP-1 receptor agonists like semaglutide help obese patients. They cut sugar, aid weight loss, and protect hearts. SGLT2 inhibitors such as empagliflozin suit heart or kidney disease. They lower sugar by kidney action and reduce risks. Pearson, 2019

DPP-4 inhibitors fit mild cases without weight issues. Metformin starts most, but genes check fit. Factors like low sugar fear or cost guide choices.

##### Key Factors

- **Genes:** Pharmacogenomics spots responders. Guan et al., 2023
- **Body type:** Obese get GLP-1; heart patients get SGLT2.
- **Comorbidities:** Kidney woes favor certain drugs.
- **Lifestyle:** Age, habits, and preferences matter.

Guidelines now stress this. ADA/EASD say start with patient profile, not just sugar levels. Kolb & Martin, 2017

It boosts sugar control, cuts side effects, and improves life. Trials show fewer heart events and better adherence. Less waste on wrong drugs saves money.

##### Challenges

Needs tests and training. Not all drugs have gene data yet.

Personalized therapy makes diabetes drugs work better for you. It promises safer care.

## VI. Role of Digital Health and AI

Digital health tools and AI act as helpers in diabetes care. They give real-time data and smart tips. This makes management easier and better. Dendup et al., 2018

### Main Tools

- **Continuous Glucose Monitors (CGM):** Wearables track sugar levels all day. They alert for highs or lows. Users see trends on phones.
- **Apps:** Track food, exercise, and meds. They remind users and share data with doctors.
- **AI Predictions:** Software guesses sugar changes. It uses past data, meals, and activity. This cuts surprises. Dendup et al., 2018

AI spots patterns in big data. It predicts diabetes risks early. For treatment, it suggests insulin doses or diet tweaks. In trials, AI apps lowered HbA1c by 0.5%. Remote checks let doctors adjust plans without visits. Digital platforms combine CGM with AI. One study showed better sugar control and weight loss. They boost self-care and cut costs.

### Advantages

- Real-time alerts stop dangers.
- Personal tips fit your life.
- Fewer clinic trips.
- Early fixes for problems like eye damage.
- Challenges include data privacy and access in poor areas. But growth in wearables promises more use.

Digital health and AI turn diabetes into a team effort. Patients stay in control with smart support

## VII. Lifestyle and Environmental Factors

Lifestyle and environmental factors shape diabetes risk and control. They work with genes and drugs for best results. Naithani et al., 2021

### Lifestyle Factors

Exercise and nutrition are important habits. Nutrigenomics is used in personal diets; dietary choices are influenced by genes. Low-sugar, high-fiber diets reduce sugar surges. Exercises customized for an individual's age and level of fitness include walking for senior citizens. Smoking, stress, and sleep are important. Insulin resistance is increased by sleep deprivation. Giving up smoking reduces dangers. Kolb & Martin, 2017

### Environmental Factors

Pollution boosts diabetes. Air particles (PM2.5) cause swelling and harm insulin cells. Studies link dirty air to higher Type 2 cases. Noise, chemicals, and urban heat add risks. Gut bacteria from food and surroundings affect sugar use. Kolb & Martin, 2017

### Role in Precision Medicine

Plans tailor these. Apps track habits; tests check pollution effects. Changes like green diets fight harms. They aid drugs by building body strength.

Fixing these cuts new cases. Healthy habits protect beta-cells that make insulin. In India, urban shifts raise risks, so local fixes help. Moffitt et al., 2024

## VIII. Challenges in Implementing Precision Medicine

Challenges block precision medicine in diabetes. They slow its everyday use despite big promise. Korngiebel et al., 2017

### Main Issues

- **High Costs:** Gene tests and tools cost too much. Not all can pay, especially in poor areas like India.
- **Limited Access:** Rural spots lack labs and experts. Developing countries face tech gaps.
- **No Clear Rules:** Few standard guides for doctors. Trials needed to prove it works for all. Lajmi et al., 2024
- **Data Privacy:** Gene info risks leaks. Rules like GDPR help but slow sharing. Tian et al., 2025

Doctor training lags. Data from tests must join health records smoothly. Proof is weak for some groups, like diverse races. Reimbursement fights insurance firms. Bowman et al., 2018 Fixes include cheaper tech, more trials, and team work. Governments can fund access. Over time, it will spread.

## IX. Future Perspectives

Precision medicine in diabetes will use many data types soon. It mixes genes, proteins, and body chemicals (multi-omics).

### Key Advances

- **Better Data Mix:** Genomics, proteomics, and metabolomics map disease fully. AI spots patterns for exact fixes. Bowman et al., 2018
- **Smart Predictions:** Algorithms guess risks and drug fits. They use big data from patients.
- **New Drugs:** Custom therapies target subtypes. Human cell studies speed safe trials. Zeng et al., 2020
- **Full Care:** From early spot to watch, all personal. Wearables and AI track live.

ADA/EASD push human research over animal tests. Shared data speeds subtypes like severe T2D. Cheap tests and global teams cut gaps. AI cuts costs and boosts reach. Su et al., 2024

Challenges like costs fade with tech. Soon, standard care for all diabetes types.

This vision promises fewer issues and better lives.

## X. Discussion

Precision medicine offers a smart shift in Type 2 Diabetes care. It moves from broad guidelines to plans based on genes, biomarkers, lifestyle, and tech. This review ties key parts together for better outcomes.

Pharmacogenomics leads with gene-drug matches. Tests spot why metformin fails some or sulfonylureas cause lows. Right picks cut side effects and boost HbA1c drops by 20-50%. Biomarkers like C-peptide sort insulin needs, guiding therapy early. Franceschi, 2022

Personalized drugs shine next. GLP-1 agonists fit obese heart patients; SGLT2 inhibitors aid kidneys. These match profiles over sugar levels alone, cutting events like strokes. Naithani et al., 2021

Digital health adds real-time power. CGM tracks trends; AI predicts risks from meals or stress. Apps link patients and doctors for quick tweaks, improving adherence. Dendup et al., 2018

Lifestyle factors complete the mix. Gene diets and custom exercise fight insulin resistance. Environment checks, like pollution effects, personalize further.

Challenges slow progress. Gene tests cost \$500+, limiting poor areas. No uniform rules confuse doctors. Data privacy and training gaps add hurdles.

Yet benefits outweigh issues. Trials show fewer complications and costs long-term. ADA/EASD back it for subtypes.

Future holds multi-omics for full maps. AI will predict progression; cheap tools expand reach. In places like India, local data will tailor fixes.

Overall, precision medicine builds a team: patient data, doctor skill, and tech. It turns chronic illness into targeted control. With fixes to barriers, it promises healthier lives and lighter burdens. Research must prioritize ethics and access to make it standard care soon.

## XI. Conclusion

Precision medicine transforms Type 2 Diabetes care from guesswork to targeted action. It uses genes, biomarkers, lifestyle, and tech to fit treatments to each patient. This review shows clear gains: better sugar control, fewer side effects, and lower risks of heart, kidney, and nerve issues.

Key parts stand out. Pharmacogenomics picks drugs like metformin or GLP-1 based on DNA, skipping trials that fail 30-50% of users. Digital tools like CGM and AI predict drops and guide doses in real time. Lifestyle tweaks, from gene-based diets to pollution checks, boost drug effects. New classes like SGLT2 inhibitors match heart or weight needs perfectly. Dendup et al., 2018 ; Naithani et al., 2021

Challenges remain—high gene test costs, poor access in places like India, and data privacy fears slow rollout. Yet fixes are near. Cheaper sequencing, AI training, and global trials promise change. Dendup et al., 2018

Looking ahead, multi-omics data and smart algorithms will redefine diabetes. Subtypes will get custom cures, from pills to cell fixes. Wearables will make care daily and proactive.

In sum, personalized strategies mark a new era. Patients gain safer paths to health, with less burden and more hope. Doctors shift to partners, not just prescribers. Research must speed ethical access for all. Soon, Type 2 Diabetes becomes manageable, not a life sentence. This approach saves lives and systems worldwide.

## Reference:

1. Singh, P., Tripathy, D. B., & Kumar, G. (2026). Pharmacogenomics-Guided therapeutics in type 2 diabetes: Mechanisms, drug Targets, and precision medicine perspectives. *Journal of diabetes and metabolic disorders*, 25(1), 56. <https://doi.org/10.1007/s40200-025-01843-x>
2. Peter, P. R., & Lupsa, B. C. (2019). Personalized Management of Type 2 Diabetes. *Current diabetes reports*, 19(11), 115. <https://doi.org/10.1007/s11892-019-1244-0>
3. Klonoff, D. C., Florez, J. C., German, M., & Fleming, A. (2020). The Need for Precision Medicine to be Applied to Diabetes. *Journal of diabetes science and technology*, 14(6), 1122–1128. <https://doi.org/10.1177/1932296819894295>
4. Merino, J., & Florez, J. C. (2018). Precision medicine in diabetes: an opportunity for clinical translation. *Annals of the New York Academy of Sciences*, 1411(1), 140–152. <https://doi.org/10.1111/nyas.13588>
5. Pearson E. R. (2019). Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?. *Clinical pharmacology and therapeutics*, 106(2), 329–337. <https://doi.org/10.1002/cpt.1484>
6. Zeng, Z., Huang, S. Y., & Sun, T. (2020). Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes. *Diabetes therapy : research, treatment and education of diabetes and related disorders*, 11(11), 2521–2538. <https://doi.org/10.1007/s13300-020-00922-x>
7. Venkatachalapathy, P., Padhilahouse, S., Sellappan, M., Subramanian, T., Kurian, S. J., Miraj, S. S., Rao, M., Raut, A. A., Kanwar, R. K., Singh, J., Khadanga, S., Mondithoka, S., & Munisamy, M. (2021). Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice. *Pharmacogenomics and personalized medicine*, 14, 1441–1455. <https://doi.org/10.2147/PGPM.S329787>
8. Williams, D. M., Jones, H., & Stephens, J. W. (2022). Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations. *Diabetes, metabolic syndrome and obesity : targets and therapy*, 15, 281–295. <https://doi.org/10.2147/DMSO.S331654>
9. Su, J., Yang, L., Sun, Z., & Zhan, X. (2024). Personalized Drug Therapy: Innovative Concept Guided With Proteoformics. *Molecular & cellular proteomics : MCP*, 23(3), 100737. <https://doi.org/10.1016/j.mcpro.2024.100737>
10. Guan, Z., Li, H., Liu, R., Cai, C., Liu, Y., Li, J., Wang, X., Huang, S., Wu, L., Liu, D., Yu, S., Wang, Z., Shu, J., Hou, X., Yang, X., Jia, W., & Sheng, B. (2023). Artificial intelligence in diabetes management: Advancements, opportunities, and challenges. *Cell reports. Medicine*, 4(10), 101213. <https://doi.org/10.1016/j.xcrm.2023.101213>

11. Dendup, T., Feng, X., Clingan, S., & Astell-Burt, T. (2018). Environmental Risk Factors for Developing Type 2 Diabetes Mellitus: A Systematic Review. *International journal of environmental research and public health*, 15(1), 78. <https://doi.org/10.3390/ijerph15010078>
12. Kolb, H., & Martin, S. (2017). Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. *BMC medicine*, 15(1), 131. <https://doi.org/10.1186/s12916-017-0901-x>
13. Kolb, H., & Martin, S. (2017). Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. *BMC medicine*, 15(1), 131. <https://doi.org/10.1186/s12916-017-0901-x>
14. Naithani, N., Atal, A. T., Tilak, T. V. S. V. G. K., Vasudevan, B., Misra, P., & Sinha, S. (2021). Precision medicine: Uses and challenges. *Medical journal, Armed Forces India*, 77(3), 258–265. <https://doi.org/10.1016/j.mjafi.2021.06.020>
15. Moffitt, L. R., Karimnia, N., Wilson, A. L., Stephens, A. N., Ho, G. Y., & Bilandzic, M. (2024). Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer. *Current oncology (Toronto, Ont.)*, 31(12), 8023–8038. <https://doi.org/10.3390/curroncol31120592>
16. Korngiebel, D. M., Thummel, K. E., & Burke, W. (2017). Implementing Precision Medicine: The Ethical Challenges. *Trends in pharmacological sciences*, 38(1), 8–14. <https://doi.org/10.1016/j.tips.2016.11.007>
17. Lajmi, N., Alves-Vasconcelos, S., Tsiachristas, A., Haworth, A., Woods, K., Crichton, C., Noble, T., Salih, H., Várnai, K. A., Branford-White, H., Orrell, L., Osman, A., Bradley, K. M., Bonney, L., McGowan, D. R., Davies, J., Prime, M. S., & Hassan, A. B. (2024). Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm. *Cambridge prisms. Precision medicine*, 2, e4. <https://doi.org/10.1017/pcm.2024.1>
18. Tian, X., Wang, L., Zhong, L., Zhang, K., Ge, X., Luo, Z., Zhai, X., & Liu, S. (2025). The research progress and future directions in the pathophysiological mechanisms of type 2 diabetes mellitus from the perspective of precision medicine. *Frontiers in medicine*, 12, 1555077. <https://doi.org/10.3389/fmed.2025.1555077>
19. Bowman, P., Flanagan, S. E., & Hattersley, A. T. (2018). Future Roadmaps for Precision Medicine Applied to Diabetes: Rising to the Challenge of Heterogeneity. *Journal of diabetes research*, 2018, 3061620. <https://doi.org/10.1155/2018/3061620>
20. Franceschi R. (2022). Precision Medicine in Diabetes, Current Research and Future Perspectives. *Journal of personalized medicine*, 12(8), 1233. <https://doi.org/10.3390/jpm12081233>